{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T02:42:49Z","timestamp":1793673769901,"version":"4.5.1"},"reference-count":54,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,30]],"date-time":"2021-09-30T00:00:00Z","timestamp":1632960000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.clinthera.2021.08.011","type":"journal-article","created":{"date-parts":[[2021,9,20]],"date-time":"2021-09-20T03:41:10Z","timestamp":1632109270000},"page":"1792-1818","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":154,"title":["Global Burden of Dry Age-Related Macular Degeneration: A Targeted Literature Review"],"prefix":"10.1016","volume":"43","author":[{"given":"Neil M.","family":"Schultz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shweta","family":"Bhardwaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Barclay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9394-2299","authenticated-orcid":false,"given":"Luis","family":"Gaspar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7912-537X","authenticated-orcid":false,"given":"Jason","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2021.08.011_bib0001","doi-asserted-by":"crossref","first-page":"e339","DOI":"10.1016\/S2214-109X(13)70113-X","article-title":"Causes of vision loss worldwide, 1990-2010: a systematic analysis","volume":"1","author":"Bourne","year":"2013","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.clinthera.2021.08.011_bib0002","series-title":"Global data on visual impairment 2010","author":"Pascolini","year":"2012"},{"key":"10.1016\/j.clinthera.2021.08.011_bib0003","doi-asserted-by":"crossref","first-page":"e106","DOI":"10.1016\/S2214-109X(13)70145-1","article-title":"Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis","volume":"2","author":"Wong","year":"2014","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.clinthera.2021.08.011_bib0004","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/8374647","article-title":"Age-related macular degeneration: new paradigms for treatment and management of AMD","volume":"2018","author":"Hern\u00e1ndez-Zimbr\u00f3n","year":"2018","journal-title":"Oxid Med Cell Longev"},{"key":"10.1016\/j.clinthera.2021.08.011_bib0005","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.neuron.2012.06.018","article-title":"Mechanisms of age-related macular degeneration","volume":"75","author":"Ambati","year":"2012","journal-title":"Neuron"},{"key":"10.1016\/j.clinthera.2021.08.011_bib0006","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1001\/archopht.1984.01040031330019","article-title":"Age-related macular degeneration and blindness due to neovascular maculopathy","volume":"102","author":"Ferris","year":"1984","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.clinthera.2021.08.011_bib0007","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1001\/jamaophthalmol.2013.6636","article-title":"Ten-year follow-up of age-related macular degeneration in the Age-Related Eye Disease Study: AREDS Report No. 36","volume":"132","author":"Chew","year":"2014","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.clinthera.2021.08.011_bib0008","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1016\/j.ophtha.2018.05.028","article-title":"Progression of geographic atrophy in age-related macular degeneration: AREDS2 Report Number 16","volume":"125","author":"Keenan","year":"2018","journal-title":"Ophthalmology"},{"key":"10.1016\/j.clinthera.2021.08.011_bib0009","series-title":"Prescribing information","author":"Macugen","year":"2016"},{"key":"10.1016\/j.clinthera.2021.08.011_bib0010","series-title":"Prescribing information","author":"Lucentis","year":"2018"},{"key":"10.1016\/j.clinthera.2021.08.011_bib0011","series-title":"Prescribing information","author":"Eylea","year":"2019"},{"key":"10.1016\/j.clinthera.2021.08.011_bib0012","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.ophtha.2012.03.053","article-title":"Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results","volume":"119","author":"Martin","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.clinthera.2021.08.011_bib0013","doi-asserted-by":"crossref","first-page":"P1","DOI":"10.1016\/j.ophtha.2019.09.024","article-title":"Age-related macular degeneration preferred practice pattern","volume":"127","author":"Flaxel","year":"2020","journal-title":"Ophthalmology"},{"key":"10.1016\/j.clinthera.2021.08.011_bib0014","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s40123-020-00325-y","article-title":"The patient experience: symptoms and impact of dry age-related macular degeneration","volume":"10","author":"Schultz","year":"2021","journal-title":"Ophthalmol Ther"},{"key":"10.1016\/j.clinthera.2021.08.011_bib0015","unstructured":"M Brouwers, ME Kho, GP Browman, et\u00a0al. AGREE II: Advancing guideline development, reporting and evaluation in healthcare. 2013. http:\/\/www.agreetrust.org\/wp-content\/uploads\/2013\/10\/AGREE-II-Users-Manual-and-23-item-Instrument_2009_UPDATE_2013.pdf. Accessed November 3, 2020."},{"key":"10.1016\/j.clinthera.2021.08.011_bib0016","unstructured":"Scottish Intercollegiate Guidelines Network. Methodology: Checklists. https:\/\/www.sign.ac.uk\/what-we-do\/methodology\/checklists\/. Accessed February 12, 2021."},{"key":"10.1016\/j.clinthera.2021.08.011_bib0017","unstructured":"National Institute for Health and Care Excellence. Single technology appraisal: User guide for company evidence submission template [PMG24]. 2015. https:\/\/www.nice.org.uk\/process\/pmg24\/chapter\/instructions-for-companies. Accessed November 3, 2020."},{"key":"10.1016\/j.clinthera.2021.08.011_bib0018","series-title":"Guidance for Industry: Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims","year":"2009"},{"key":"10.1016\/j.clinthera.2021.08.011_bib0019","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1167\/iovs.13-13096","article-title":"Prevalence and risk factors of age-related macular degeneration in Korea: the Korea National Health and Nutrition Examination Survey 2010\u20132011","volume":"55","author":"Cho","year":"2014","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.clinthera.2021.08.011_bib0020","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.ophtha.2004.10.047","article-title":"Risk factors for the incidence of advanced age-related macular degeneration in the Age-Related Eye Disease Study (AREDS): AREDS report no. 19","volume":"112","author":"Clemons","year":"2005","journal-title":"Ophthalmology"},{"key":"10.1016\/j.clinthera.2021.08.011_bib0021","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1007\/s00417-014-2591-9","article-title":"Prevalence of age-related macular degeneration in a large European cohort: results from the population-based Gutenberg Health Study","volume":"252","author":"Korb","year":"2014","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.clinthera.2021.08.011_bib0022","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1038\/eye.2017.139","article-title":"Age-related macular degeneration and mortality: the Melbourne Collaborative Cohort Study","volume":"31","author":"McGuinness","year":"2017","journal-title":"Eye"},{"key":"10.1016\/j.clinthera.2021.08.011_bib0023","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.ophtha.2017.10.028","article-title":"Association of mortality with ocular diseases and visual impairment in the Age-Related Eye Disease Study 2: Age-Related Eye Disease Study 2 Report Number 13","volume":"125","author":"Papudesu","year":"2018","journal-title":"Ophthalmology"},{"key":"10.1016\/j.clinthera.2021.08.011_bib0024","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1016\/j.ophtha.2003.11.010","article-title":"Risk factors for incident age-related macular degeneration: Pooled findings from 3 continents","volume":"111","author":"Tomany","year":"2004","journal-title":"Ophthalmology"},{"key":"10.1016\/j.clinthera.2021.08.011_bib0025","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1001\/jamaophthalmol.2016.0588","article-title":"Prevalence of age-related macular degeneration in Chinese American adults: the Chinese American Eye Study","volume":"134","author":"Varma","year":"2016","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.clinthera.2021.08.011_bib0026","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1016\/j.ophtha.2017.05.035","article-title":"Prevalence of age-related macular degeneration in Europe: the past and the future","volume":"124","author":"Colijn","year":"2017","journal-title":"Ophthalmology"},{"key":"10.1016\/j.clinthera.2021.08.011_bib0027","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1080\/09286586.2016.1259422","article-title":"Age-related macular degeneration and mortality: a systematic review and meta-analysis","volume":"24","author":"McGuinness","year":"2017","journal-title":"Ophthalmic Epidemiol"},{"key":"10.1016\/j.clinthera.2021.08.011_bib0028","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/j.ajo.2013.06.007","article-title":"Prevalence and characteristics of age-related macular degeneration in the Japanese population: the Nagahama study","volume":"156","author":"Nakata","year":"2013","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.clinthera.2021.08.011_bib0029","doi-asserted-by":"crossref","first-page":"245","DOI":"10.12688\/f1000research.10664.1","article-title":"Recent advances in the management of dry age-related macular degeneration: a review","volume":"6","author":"Bandello","year":"2017","journal-title":"F1000Res."},{"key":"10.1016\/j.clinthera.2021.08.011_bib0030","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.2147\/OPTH.S92359","article-title":"Geographic atrophy in patients with advanced dry age-related macular degeneration: current challenges and future prospects","volume":"9","author":"Danis","year":"2015","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.clinthera.2021.08.011_bib0031","article-title":"Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration","volume":"11","author":"Evans","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.clinthera.2021.08.011_bib0032","series-title":"Miniature lens system implantation for advanced age-related macular degeneration","year":"2016"},{"key":"10.1016\/j.clinthera.2021.08.011_bib0033","series-title":"Age-related macular degeneration: NICE guideline [NG82]","year":"2018"},{"key":"10.1016\/j.clinthera.2021.08.011_bib0034","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s40123-017-0086-6","article-title":"A review of current and future management of geographic atrophy","volume":"6","author":"Sacconi","year":"2017","journal-title":"Ophthalmol Ther"},{"key":"10.1016\/j.clinthera.2021.08.011_bib0035","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/164_2016_36","article-title":"Dry age-related macular degeneration pharmacology","volume":"242","author":"Wright","year":"2017","journal-title":"Handb Exp Pharmacol"},{"key":"10.1016\/j.clinthera.2021.08.011_bib0036","series-title":"EURETINA Conference","article-title":"Subretinal implantations of PRIMA wireless photovoltaic chip, a new surgical technique for atrophic dry agerelated macular degeneration: technical feasibility and early results","author":"Le Mer","year":"2018"},{"key":"10.1016\/j.clinthera.2021.08.011_bib0037","series-title":"EURETINA Conference","article-title":"Complement C5 inhibition as a potential treatment for geographic atrophy secondary to dry agerelated macular degeneration","author":"Mon\u00e9s","year":"2018"},{"key":"10.1016\/j.clinthera.2021.08.011_bib0038","doi-asserted-by":"crossref","first-page":"e10422","DOI":"10.1097\/MD.0000000000010422","article-title":"Therapeutic effects of various therapeutic strategies on non-exudative age-related macular degeneration: A PRISMA-compliant network meta-analysis of randomized controlled trials","volume":"97","author":"Wei","year":"2018","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.clinthera.2021.08.011_bib0039","series-title":"2018 AAO Meeting Retina Subspecialty Day","article-title":"Brimonidine DDS safety and efficacy in patients with geographic atrophy secondary to age-related macular degeneration","author":"Freeman","year":"2018"},{"key":"10.1016\/j.clinthera.2021.08.011_bib0040","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1007\/s10198-002-0104-y","article-title":"The epidemiology, economics and quality of life burden of age-related macular degeneration in France, Germany, Italy and the United Kingdom","volume":"3","author":"Bonastre","year":"2002","journal-title":"Eur J Health Econ"},{"key":"10.1016\/j.clinthera.2021.08.011_bib0041","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S0008-4182(05)80070-5","article-title":"Age-related macular degeneration: economic burden and value-based medicine analysis","volume":"40","author":"Brown","year":"2005","journal-title":"Can J Ophthalmol"},{"key":"10.1016\/j.clinthera.2021.08.011_bib0042","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/s10198-003-0198-x","article-title":"Direct medical costs of age-related macular degeneration in Italian hospital ophthalmology departments. A multicenter, prospective 1-year study","volume":"5","author":"Garattini","year":"2004","journal-title":"Eur J Health Econ"},{"key":"10.1016\/j.clinthera.2021.08.011_bib0043","first-page":"37","article-title":"Resource utilization and costs of age-related macular degeneration","volume":"27","author":"Halpern","year":"2006","journal-title":"Health Care Financ Rev"},{"key":"10.1016\/j.clinthera.2021.08.011_bib0044","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.ajo.2012.04.017","article-title":"Patterns and costs associated with progression of age-related macular degeneration","volume":"154","author":"Schmier","year":"2012","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.clinthera.2021.08.011_bib0045","doi-asserted-by":"crossref","first-page":"319","DOI":"10.2165\/00019053-200624040-00003","article-title":"The burden of age-related macular degeneration","volume":"24","author":"Schmier","year":"2006","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.clinthera.2021.08.011_bib0046","first-page":"A160","article-title":"Geographic atrophy disease burden: Need for better characterization","volume":"20","author":"Schmier","year":"2017","journal-title":"Value Health"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2021.08.011_bib0047","first-page":"123","article-title":"Engaging patients, caregivers, and physicians to understand the burden of illness of geographic atrophy","volume":"26","author":"Schmier","year":"2017","journal-title":"Qual Life Res"},{"key":"10.1016\/j.clinthera.2021.08.011_bib0048","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2016-011504","article-title":"How does age-related macular degeneration affect real-world visual ability and quality of life? A systematic review","volume":"6","author":"Taylor","year":"2016","journal-title":"BMJ Open"},{"key":"10.1016\/j.clinthera.2021.08.011_bib0049","first-page":"2811","article-title":"Patient-reported visual function in patients with geographic atrophy secondary to age-related macular degeneration (AMD): baseline characteristics of the BAM114341 cohort","volume":"56","author":"Wang","year":"2015","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.clinthera.2021.08.011_bib0050","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1097\/OPX.0b013e3182962318","article-title":"Patient and public preferences for health states associated with AMD","volume":"90","author":"Butt","year":"2013","journal-title":"Optom Vis Sci"},{"key":"10.1016\/j.clinthera.2021.08.011_bib0051","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1001\/jamaophthalmol.2016.0794","article-title":"Age-related macular degeneration and quality of life in Latinos: the Los Angeles Latino Eye Study","volume":"134","author":"Choudhury","year":"2016","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.clinthera.2021.08.011_bib0052","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/1471-2415-14-78","article-title":"The prevalence of anxiety and depression in people with age-related macular degeneration: a systematic review of observational study data","volume":"14","author":"Dawson","year":"2014","journal-title":"BMC Ophthalmol"},{"key":"10.1016\/j.clinthera.2021.08.011_bib0053","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0002-9394(99)00169-5","article-title":"Influence of age-related maculopathy on visual functioning and health-related quality of life","volume":"128","author":"Mangione","year":"1999","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.clinthera.2021.08.011_bib0054","series-title":"Patient-Focused Drug Development: Collecting Comprehensive and Representative Input. Draft Guidance for Industry, Food and Drug Administration Staff, and Other Stakeholders","year":"2018"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291821003106?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291821003106?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T08:56:25Z","timestamp":1758963385000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291821003106"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":54,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["S0149291821003106"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2021.08.011","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Global Burden of Dry Age-Related Macular Degeneration: A Targeted Literature Review","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2021.08.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}